OTCWagon Issues Update on Immunoprecise Antibodies Ltd. (IPA)

VICTORIA, British Columbia - April 20, 2020 - PRLog -- Immunoprecise signs research licence deal with Janssen

Immunoprecise Antibodies Ltd., through its subsidiary Talem Therapeutics, has entered into a research licence agreement with Janssen Research & Development LLC, providing Janssen exclusive access to a panel of novel, monoclonal antibodies against an undisclosed target. Pursuant to the agreement, Janssen holds an option to acquire all commercial rights to the antibodies. The financial details of the transaction have not been disclosed.

"This agreement validates Talem's business concept in early antibody discovery and development," said Ilse Roodink, chairwoman of Talem's scientific advisory committee and scientific director at IPA Europe. "It is a significant milestone to see this exclusive agreement through Talem finalized with Janssen, a company so well positioned to further develop and maximize the potential of these lead candidates for clinical applications."

"Talem continues to build a therapeutic program pipeline for commercial partnering, thus optimizing shareholder value creation based on IPA's infrastructure across Europe and North America," added Jennifer Bath, president and CEO of Immunoprecise Antibodies.

About Immunoprecise Antibodies Ltd.

Immunoprecise is a full-service, therapeutic antibody discovery contract research organization offering species agnostic, multiformat, characterized and engineered, human monoclonal antibodies, on an abbreviated time frame, for its pharmaceutical clients.

About Talem Therapeutics LLC

Talem Therapeutics is focused on the discovery and development of therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation and rare/specialty diseases.

With direct access to world-class expedited and end-to-end technologies in the antibody discovery and development process, Talem accelerates novel, therapeutic antibody treatments to the clinic through strategic alliances and partnerships.

OTCWagon is extremely happy to be working with IPA and bringing them to our savvy investors. We look forward to further advancements and updates with Immunoprecise Antibodies Ltd. (IPA)